Insight Molecular Diagnostics Inc. (IMDX)
NASDAQ: IMDX · Real-Time Price · USD
7.32
+0.63 (9.42%)
At close: Feb 6, 2026, 4:00 PM EST
7.37
+0.05 (0.68%)
After-hours: Feb 6, 2026, 4:10 PM EST
IMDX Revenue
Insight Molecular Diagnostics had revenue of $260.00K in the quarter ending September 30, 2025, with 126.09% growth. This brings the company's revenue in the last twelve months to $4.40M, up 520.87% year-over-year. In the year 2024, Insight Molecular Diagnostics had annual revenue of $1.88M with 25.15% growth.
Revenue (ttm)
$4.40M
Revenue Growth
+520.87%
P/S Ratio
44.58
Revenue / Employee
$89,837
Employees
49
Market Cap
209.82M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.88M | 378.00K | 25.15% |
| Dec 31, 2023 | 1.50M | 545.00K | 56.89% |
| Dec 31, 2022 | 958.00K | -1.24M | -56.41% |
| Dec 31, 2021 | 2.20M | 982.00K | 80.76% |
| Dec 31, 2020 | 1.22M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Myriad Genetics | 825.30M |
| OPKO Health | 642.07M |
| Castle Biosciences | 343.53M |
| Fulgent Genetics | 315.55M |
| FONAR | 105.43M |
| MDxHealth | 103.07M |
| Biodesix | 80.17M |
| Prenetics Global | 77.08M |
IMDX News
- 26 days ago - IMDX Supports AST and ASHI STAR Working Group's Call for Decentralized Transplant Monitoring - GlobeNewsWire
- 4 weeks ago - iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation - GlobeNewsWire
- 4 weeks ago - iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch - GlobeNewsWire
- 4 weeks ago - iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion - GlobeNewsWire
- 3 months ago - Insight Molecular Diagnostics Inc. (IMDX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch - GlobeNewsWire
- 3 months ago - iMDx to Release Third Quarter 2025 Results on November 10 and Attend Stephens Annual Investment Conference the Following Week - GlobeNewsWire
- 4 months ago - iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch - GlobeNewsWire